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Killer cell immunoglobulin-like receptor (KIR) genes are known to play a role in the 
acute phase of hepatitis C virus (HCV) infection. The present study investigated their 
roles in chronic HCV (CHCV) infection by analyzing the phenotypes and function of 
natural killer (NK) and T cells that express KIRs. T cells from CHCV patients showed 
a more differentiated phenotype, and NK  cells exhibited an activated profile. These 
observations are consistent with the increased expression of the degranulation marker 
CD107a observed after PMA stimulation. We explored the correlations between the 
expression of KIR genes and lectin type-C receptors with clinical factors that predict 
progression to fibrosis and cirrhosis. The expression levels of KIR2DS3 and the func-
tional alleles of KIR2DS4-FL were increased in patients with intermediate and high viral 
loads. Homozygous KIR2DS4 was also associated with the presence of cirrhosis. In the 
group of individuals with a shorter infection time who developed cirrhosis, we detected 
decreased expression of KIR3DL1 in CD56dim NK cells in the presence of its ligand. 
Similarly, in the group of patients with late CHCV infections complicated with cirrhosis, 
we detected lower expression of the strong inhibitory receptor NKG2A in CD56bright 
NK cells. We also detected an increase in NKG2C expression in CD56dim NK cells in 
CHCV patients who displayed high necroinflammatory activity. Decreased KIR3DL2 
expression in CD56dim and CD56bright NK cells was associated with a high body mass 
index, and KIR3DL2 expression may be one factor associated with the more rapid 
progression of CHCV to fibrosis in patients.
Keywords: chronic hcV, liver, killer cell immunoglobulin-like receptor, natural killer cells, T cells
Abbreviations: CHCV, chronic HCV; LMCs, human liver mononuclear cells; NK  cell, natural killer cell; KIR, killer cell 
immunoglobulin-like receptor; NKT cell, natural killer T cell.
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iMPOrTance
Our results indicate that increased expression of an activated 
receptor or decreased expression of the inhibitory counterpart 
may be associated with a worse clinical evolution during the 
chronic phase of the hepatitis C virus (HCV) infection, in con-
trast to the acute phase of HCV infection. These changes should 
be evaluated in the context of a more differentiated/activated state 
of peripheral blood and liver T cells and natural killer (NK) cells 
and their increased capacity to degranulate, which may reflect a 
potential increase in cytotoxic activity.
inTrODUcTiOn
Hepatitis C virus infects over 170 million people worldwide 
(1). During the acute phase, a small proportion of individuals 
can naturally clear HCV using NK  cells. Based on studies of 
health-care workers exposed to small amounts of HCV, activated 
NK cells may participate in controlling acute infection and sub-
sequent HCV-specific T-cell response (2). NK cells from patients 
who later cleared the infection have a greater antiviral effect 
in vitro than NK cells from patients who progressed to a chronic 
HCV (CHCV) infection (3). According to early genetic studies, 
spontaneous HCV clearance is observed in patients with the 
KIR2DL3/HLA-C1 compound genotype, which results in a lower 
activation threshold for NK cells (4). NK cells are traditionally 
regarded as first-line effectors of the innate immune response and 
may also have a distinct role in chronic infection. If early resolu-
tion does not occur, NK cell activity decreases and the adaptive 
immune system begins to respond in a specific way. However, if 
the adaptive immune system does not succeed in eradicating the 
virus, the infection becomes a persistent and chronic infection in 
the presence of continuous viral replication, potentially leading to 
the development of liver cirrhosis and hepatic cellular carcinoma. 
The innate immune response to an infection is likely to influence 
the type of adaptive immune response that develops and will 
ultimately determine whether the virus is cleared or develops into 
a chronic infection [reviewed in Rehermann (5)]. NK cells are 
known to kill HCV-infected hepatocytes and produce IFN-γ, the 
main antiviral cytokine (6). NK cells are divided into functionally 
distinct subsets based on their level of CD56 surface expression: 
the mainly cytotoxic CD56dim population and the more immu-
noregulatory cytokine-producing CD56bright NK cell subset. The 
functions of both NK  cell subsets are modulated by inhibitory 
and activating signals provided by distinct classes of receptors. 
Inhibitory receptors include the polymorphic system, killer 
cell immunoglobulin-like receptors (KIR) (7), and a member 
of the C-type lectin-like receptor family, CD94/NKG2A, which 
recognizes HLA-E (8). Activating receptors include natural cyto-
toxicity-inducing receptors (NKp30, NKp44, and NKp46), the 
lectin-like receptors NKG2C (expressed as a dimer with CD94), 
and NKG2D, the signaling lymphocyte activation molecule 
family receptors (9), and the FcγRIIIa receptor (CD16), which 
mediates antibody-dependent cytotoxicity (10). The role of KIR 
genes in the chronic stage of infection has been mostly identified 
at the genomic level (11, 12) or has been associated with the role 
of HCV in the development of HCV-associated diseases (13, 14).
The role of T  cells in HCV infection has been studied 
extensively (15). Because the liver is the target of HCV infec-
tion, studies aiming to understand the difference between liver 
and peripheral blood T cells are necessary. Liver CD3+ cells are 
characterized by a high percentage of CD3+CD8+ cells and a 
subset of CD3+CD56+ cells (16, 17). CD8+ T cells exist in at least 
three different states of reactivity: naïve CD8+ T cells with low 
reactivity, activated (effector) CD8+ T cells with high reactivity, 
and memory CD8+ T  cells with intermediate reactivity. The 
overall memory CD8+ T  cell compartment consists of central 
and memory subsets, which are recognized based on their 
phenotype and function (18, 19). Recently, we reported high 
levels of KIR receptor expression in peripheral blood and liver 
CD3+CD56+ cells and in liver T cells (20).
The aim of the present work was to examine the correlations 
between the KIR genotype and KIR protein expression with 
clinical aspects related to the development of CHCV infection. 
In particular, we investigated the roles of NK and T cells in CHCV 
patients and analyzed the KIR genotype and KIR protein expres-
sion on peripheral blood and liver cells. We next explored the 
putative associations of KIR genes and lectin-type receptors with 
clinical factors that predict progression to fibrosis and cirrhosis.
PaTienTs anD MeThODs
The cohort included 273 healthy subjects and 351 adult individuals 
with CHCV infection, 117 of whom had not received any treat-
ment. In addition, liver samples were collected from 23 healthy 
adult individuals and 6 CHCV subjects who were undergoing 
transplantation. Patients and controls were recruited from the 
Hepatology Services of Hospital de Enfermedades Infecciosas “F. 
J. Muñiz,” Hospital de Clínicas “José de San Martin,” and Hospital 
Universitario Austral. The healthy controls were matched with 
patients according to gender and ethnicity. All subjects belong 
to a homogeneous Latin American Caucasian population that is 
primarily composed of second- or third-generation Argentines, 
most of whom have a Spanish or Italian background. A small 
number of Amerindians and black individuals are living in 
Argentina but these individuals were not enrolled in the present 
study. All controls were examined and found to be negative for 
HIV, hepatitis B virus (HBV), and HCV. All CHCV patients were 
negative for HIV and HBV.
The study was approved by the Investigation and Ethics 
Committee and Institutional Review Board of the Hospital de 
Clínicas José de San Martín and the experiments were performed 
in accordance with the ethical guidelines of the 1975 Declaration 
of Helsinki. All samples obtained during the liver transplant were 
identified by a transplant procedure number provided by INCUCAI 
and did not include the name of the donor. None of the transplant 
donors were from a vulnerable population and all donors or next 
of kin provided voluntary written informed consent.
clinical characteristics of Patients with 
chcV infections
A summary of the clinical characteristics is provided in Table 1. 
Serum anti-HCV antibody titers of all patients were determined 
Table 1 | Clinical characteristics of the patients with chronic HCV (CHCV) 
infections.
chcV clinical features Median or factor (n) range
Years 51 years (20–77)
Sex F:166, M:185
Genotype 1 (n: 37), 2 (n: 14), 3  
(n: 16), 4 (n: 3)
Body mass index 26 (n: 47) (18–40)
Viral load 770,442 IU/ml (n: 96) (500–2,000,000)
Transaminases 1.8 (ratio) (n: 291) (0.6–8.4)
Time since infection 27 years (1–61)
Fibrosis METAVIR: F0 (n:7), F1 (n:18),  
F2 (n:13), F3 (n:8), F4 (n:9)
FibroScan: F0 (n:16), F1 (n:13), 
F2 (n:20), F3 (n:8), F4 (n:20)
Ishak: E1 (n:29), E2 (n:3), E3  




METAVIR: A0 (n:2), A1 (n: 27),  
A2 (n:17), >A3 (n:9)
Cirrhosis 171 individuals
Table 2 | Donor data: age, sex, and cause of death.
age sex cause of death
60 F Hemorrhagic stroke
56 F Hemorrhagic stroke
25 M Traumatic brain injury
40 F Hemorrhagic stroke
50 F Hemorrhagic stroke
28 M Traumatic brain injury
43 F Traumatic brain injury
20 M Traumatic brain injury
58 F Hemorrhagic stroke
20 M Hypoxic brain injury
19 M Traumatic brain injury
19 M Traumatic brain injury
35 M Hemorrhagic stroke
49 M Hemorrhagic stroke
55 F Hemorrhagic stroke
33 M Traumatic brain injury
27 M Traumatic brain injury
18 M Traumatic brain injury
23 M Traumatic brain injury
52 M Hemorrhagic stroke
56 M Hemorrhagic stroke
45 F Hemorrhagic stroke
55 F Hemorrhagic stroke
3
Podhorzer et al. Association Between KIRs and CHCV
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 8 | Article 1912
using the third-generation ELISA technique (4.0 Murex-Abbot), 
and detectable levels of viral RNA were measured using qualita-
tive PCR (AMPLICOR® Hepatitis C Virus Test 2.0). Only periph-
eral blood samples from patients who had not been treated were 
used to analyze the expression of markers, functional capacity, 
and correlations with factors predictive of evolution to fibrosis. 
In contrast, samples from treated patients were included in the 
genomic study. Liver samples from individuals with CHCV 
infection were obtained during the surgical procedure for the 
liver transplant. Data regarding sex, body mass index (BMI), 
the time when patients became infected (when this information 
was available), viral load, liver transaminase levels, inflammatory 
activity, and the degree of fibrosis were obtained to examine 
factors that predicted clinical progression. For various reasons 
related to the origin of the samples, we were not able to include 
all these data from the whole cohort of CHCV patients. Viral load 
was measured in 96 patients using the qRT-PCR technique with 
the COBAS® TaqMan® HCV Test v2.0 kit (Roche). Individuals 
were separated into three groups according to the obtained 
viral load: 12 individuals with a low viral load (<100,000  IU/
ml), 25 individuals with a moderate viral load (between 100,000 
and 500,000  IU/ml) and 59 individuals with a high viral load 
(≥500,000 IU/ml).
The COBAS® HCV GT kit (Roche) was used to analyze the 
different viral genotypes; this kit distinguishes between genotypes 
1 and 6 using a highly sensitive real-time PCR assay. The analysis 
of 115 CHCV patients showed the following distribution of viral 
genotypes: genotype 1:37 cases, genotype 2:14 cases, genotype 
3:16 cases, and genotype 4:3 cases. BMI was obtained from 47 
patients, 22 of whom had normal weight (BMI  ≤  25) and 25 
were overweight (BMI  >  25). The transaminase activities of 
SGOT or aspartate aminotransferase (AST) and SGPT or alanine 
aminotransferase (ALT) were measured in 291 HCV patients, 90 
of whom had normal or slightly increased activity levels and 201 
had values elevated by more than twofold relative to the upper 
limit of normal.
To evaluate the degree of inflammation and fibrosis, 140 liver 
biopsies were performed using a percutaneous or trans-jugular 
method. Fifty-five cases were evaluated using the METAVIR 
system. This system classifies fibrosis in stages ranging from F0 
to F4, and in the present study, higher stages (F3 and F4) were 
considered to indicate cirrhosis. The METAVIR system also clas-
sifies necroinflammatory activity into stages A0–A3; in our study, 
stages A2 and A3 were considered to indicate high necroinflam-
matory activity and were associated with a more rapid progression 
to cirrhosis (21). Eighty-five individuals were evaluated using the 
Ishak score, which classifies fibrosis in stages ranging between 
E1 and E6. For this study, we considered the stages E5 and E6 to 
indicate cirrhosis. In 77 individuals, the degree of fibrosis was 
obtained using the non-invasive method of transient elastography 
(Fibroscan®), which classifies fibrosis in stages ranging from F0 
to F4, and stages F3 and F4 were considered to indicate cirrhosis. 
Finally, in 134 patients, the presence or absence of cirrhosis was 
simply determined by the combination of the results of clinical 
studies and ultrasonography.
collection of Perfused liver samples
Samples were collected from donor livers and recipients using 
methods previously described by Kelly et  al. (22). During 
orthotopic liver transplantation, 23 samples from donor liv-
ers (Table  2) and 6 samples from CHCV-infected recipients 
were collected at the Austral University Hospital. All samples 
were identified by a transplant procedure number provided by 
INCUCAI that did not include the name of the donor and were 
collected from the Austral University Hospital, Buenos Aires, 
Argentina. After brain death, the procuration team working 
in the intensive care unit required the next of kin to sign the 
donor consent form for transplantation and participation in the 
research project.
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During retrieval (at the time of exsanguination), the donor 
aorta and superior mesenteric vein were flushed with University 
of Wisconsin (UW) solution (Bristol-Myers Squibb, Uxbridge, 
UK) or with HTK (histidine–tryptophan–ketoglutarate) solution. 
After excising the organ, the liver was again flushed with UW 
solution until all blood was removed and the perfused solution 
appeared clear. At implantation and after completing the upper 
inferior cava anastomosis, livers were flushed with Ringer’s lactate 
solution through the portal vein at 4°C to wash out the UW before 
reperfusion. The perfused hepatic fluid was collected from the 
inferior cava vein (600–1,200 ml).
liver samples from Patients with chcV 
infections
After each operation, the liver from the CHCV patient was 
placed in a container with a physiological solution, and 500 ml 
of lactated Ringer’s solution was infused through the portal vein; 
after traversing the organ, this solution was recovered through the 
suprahepatic veins. The liver remained in this solution during the 
transplant process. Subsequently, this solution was discarded, and 
the infusion of 500 ml of lactated Ringer’s solution through the 
portal vein was repeated; the solution from the second infusion 
was then collected.
Mononuclear cell isolation
Peripheral blood mononuclear cells (PBMCs) from adult healthy 
controls and liver mononuclear cells (LMCs) from healthy cadav-
eric donors and recipients were obtained using Ficoll-Hypaque 
density gradient centrifugation (GE Healthcare Biosciences, 
Uppsala, Sweden).
Monoclonal antibodies and Flow 
cytometry
Peripheral blood mononuclear cells and LMCs were stained with 
unconjugated antibodies against KIR 3DL1/3DL2 (clone 5.133, 
courtesy of Dr. M. Colonna), KIR 2DL2/2DS2/2DL3 (clone CHL, 
courtesy of Dr. S. Ferrini), KIR 2DL1/2DS1 (clone HPMA4), 
KIR 2DL1/2DS1/2DS3 (clone HP3E4), CD94 (clone 3D9), and 
NKG2A (clone Z199, courtesy of Dr. M. Bottet) or unconjugated 
IgG1, IgG2a, IgG2b, and IgM isotype control antibodies (Becton 
Dickinson, San Jose, CA, USA). In addition, mouse monoclonal 
antibodies against 3DL1-FITC, 2DL3-PE (Becton Dickinson, 
San Jose, CA, USA), 2DS4-PE, NKG2C-PE (R&D Systems, MN, 
USA), NKp44-PE, NKp46-PE, 2B4-FITC, CD16-FITC, CD57-
APC, CD8-PE/APC, CD4-FITC, CD45RA-PE-Cy7, CD28-PE, 
CD27-PE-CF594, CCR7-FITC, CD11b-FITC, CD161-APC/
PE, HLA-DR-FITC, and labeled IgG1 and IgG2a isotype con-
trol antibodies (Biolegend, San Diego, CA, USA) were used. 
Cells were incubated with the above mentioned antibodies at 
room temperature (RT) for 30  min, then were washed twice 
with 1  ml of 1× PBS and centrifuged at 500  g for 5  min. For 
unconjugated antibodies, a subsequent incubation with 3  µl of 
FITC- or PE-conjugated antimouse immunoglobulin antibody 
(Dako, Glostrup, Denmark) was performed for 30  min at RT. 
After washing, 3  µl of normal mouse serum was added. Cells 
were incubated with 3  µl of anti-CD3 (Becton Dickinson, San 
Jose, CA, USA) conjugated to PerCP/FITC and 5 µl of anti-CD56 
conjugated to PE/APC (Becton Dickinson, San Jose, CA, USA) or 
to BV421 (Biolegend, San Diego, CA, USA) for 15 min at RT to 
analyze labeling corresponding to the NK, NKT (CD3+CD56+), 
and T cells. A suitable fluorochrome combination was performed 
for each labeling scheme. Liver samples were also incubated 
with the anti-CD45 pan-leukocyte marker (Becton Dickinson) 
conjugated to APC-H7. After washes with 1× PBS, cells were 
fixed with 2% paraformaldehyde and subsequently analyzed 
using a FACSAria II flow cytometer (Becton Dickinson). The 
results were analyzed using FlowJo 7.6.2 software (Tree Star, Inc., 
Ashland, OR, USA). All analyses of a particular population of 
interest were based on the gating of at least 100,000 events. The 
surface expression of three KIR receptors was indirectly inferred 
as follows: the antibody 3DL1/3DL2 showed two populations 
with different mean fluorescence intensities, the lower population 
corresponded to 3DL2 and the upper population to 3DL1. In all 
cases, the expression of the upper population was compared with 
the monoclonal antibody against 3DL1 and a significant differ-
ence was not detected. The expression of 2DS3 was identified by 
subtracting the expression detected using the 2DL1/2DS1/2DS3 
antibodies from 2DL1/2DS1 expression. The expression of 2DS1 
was deduced by subtracting the expression of 2DL1 from the 
expression detected using the 2DL1/2DS1 antibody. The expres-
sion of 2DL2/2DS2 was inferred after subtracting the expression 
detected by the anti-2DL3 antibody to the expression detected 
by the anti-2DL2/2DS2/2DL3 antibody. In all cases, the presence 
of the KIR gene was verified. When using polyclonal antibod-
ies, the correct method to deduce the expression of a single KIR 
protein is to use polyclonal and monoclonal antibodies together 
in the same tube (23); however, because of the limited number 
of fluorochrome combinations, we performed the reactions in 
different tubes and inferred the expression of single KIR proteins 
(see Figure S1 in Supplementary Material).
We distinguished between apoptotic and viable cells based on 
differences in forward and side scatter, and the results showed 
a good correspondence with the results obtained using FITC-
annexin staining (24, 25). We previously assessed the quality 
of the results through dead cell staining, showing that dead cell 
discrimination by forward/side scatter displayed an excellent 
correlation with the results obtained using the LIVE/DEAD® 
Fixable Aqua Dead Cell Stain Kit, which specifically stains 
lymphocytes.
Kir and hla-a, b, and c Typing by Pcr 
sequence-specific Oligonucleotide 
Probing (ssOP)
The conditions used to identify the presence or absence of each 
KIR gene have been documented previously (20). Briefly, two PCR 
amplifications were performed: PCR-1 amplified the combined 
D1 and D2 domains and PCR-2 amplified the transmembrane 
and cytoplasmic regions. Nineteen 5′-digoxigenin-labeled probes 
were used in the SSOP approach, with 13 for PCR-1 and 6 for 
PCR-2. The KIR gene content in each individual was inferred after 
analyzing the combinations of all probes. The KIR2DS4 gene was 
amplified by PCR with previously described primers to analyze 
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the cell membrane-anchored receptor (designated KIR2DS4-FL 
or FL) and a truncated soluble protein (designated KIR1D), which 
is generated when exon 5 contains a 22-bp deletion. HLA-A, B, 
and C genotyping was performed for sequences from exons 2 and 
3. The primers and conditions for PCR amplification were the 
same as those described by Cereb et al. (26). HLA-C SSOP typing 
was also conducted using two probes (5′-digoxigenin label); one 
of the probes (5′-TGACCGAGTGAACCTGC-3′) was specific 
for the HLA-C alleles that belong to the C1 group (Asn 80), and 
the other probe (sequence: 5′-ACCGAGTGAGCCTGCG-3′) 
anneals with the HLA-C alleles that belong to the C2 group (Lys 
80).
Functional studies
Mononuclear cells obtained from the liver or peripheral blood 
were placed in 24-well plates at a density of 1 × 106 lymphocytes 
per well and cultured in 1 ml of complete RPMI medium. Three 
wells were used for each sample according to the following 
scheme: (1) cells stimulated with the target antibody to study 
functionality, (2) cells stimulated with the isotype control, and 
(3) unstimulated cells that served as a negative control. Twenty 
microliters of the anti-CD107a antibody (Becton Dickinson) 
conjugated to FITC were added to wells 1 and 3 and 20 µl of the 
FITC-conjugated IgG1 (Becton Dickinson) isotype control was 
placed in well 2 as a control. PMA (phorbol 12-myristate 13-ace-
tate; Sigma) was added to wells 1 and 2 at a final concentration 
of 25 ng/ml, and ionomycin (calcium salt from Streptomyces con-
globatus; Sigma) was added at a final concentration of 0.5 µg/ml. 
The culture plate was incubated for 1  h at 37°C in a 5% CO2 
atmosphere. One microliter of monensin (BD-Golgi Stop Protein 
Transport Inhibitor, BD Biosciences) was then added to all wells, 
and the cells were incubated for an additional 5 h. The contents 
of each well were transferred to FACS tubes; cells were washed 
with 1 ml of 1× PBS/A and centrifuged at 500 g for 5 min. In all 
samples, cell surface labeling was performed with the following 
monoclonal antibodies: 3  µl of anti-CD3 conjugated to PerCP 
(Becton Dickinson) and 5  µl of anti-CD56 conjugated to APC 
(Becton Dickinson). Pan-leukocyte anti-CD45 conjugated to 
APC-H7 (Becton Dickinson) was added to the liver samples. 
After a 20-min incubation at RT, cells were washed twice with 
1× PBS/A. During intracytoplasmic labeling, cells were treated 
with 100  µl of 1× fixation and permeation solution (Cytofix/
Cytoperm, BD Biosciences) for 20 min at 4°C, washed twice with 
1 ml of 1× Perm/Wash buffer (Becton Dickinson), and centri-
fuged at 500 g for 5 min. Twenty microliters of IgG1 isotype PE 
control (Becton Dickinson) were added to well 2, and 20 µl of 
anti-IFNγ conjugated to PE (Becton Dickinson) were placed in 
wells 1 and 3; then, the samples were incubated for 30  min at 
4°C. Cells were washed with 1× Perm/Wash buffer, the pellet was 
suspended in 200 µl of 1× PBS/A, and the cells were fixed with 
2% paraformaldehyde. Finally, the cells were analyzed using a 
FACSAria II flow cytometer (Becton Dickinson).
statistical analysis
The HLA allele frequencies and expression of KIR genes in the 
patients and controls were compared using Fisher’s exact test to 
evaluate significant differences, and the p-value was corrected 
with the Bonferroni method when appropriate. Additionally, 
3 × 2 contingency tables were analyzed using the Chi-square test 
for independent samples or the maximum likelihood method 
when appropriate (viral load factor). The Mann–Whitney U test 
was used to compare independent groups. Spearman’s test was 
used to establish correlations. For all statistical analyses, we used 
GraphPad Prism 5 (GraphPad Software). Data are presented 
as medians and ranges. Reported p-values are two-tailed, and 
p < 0.05 was considered significant.
resUlTs
Typing of hla and Kir genes in chcV 
Patients
No significant differences in the typing of HLA-A, HLA-B, and 
HLA-C genes were observed between HCV patients (n =  351) 
and healthy individuals (n = 273) (Table 3).
The KIR genotyping results did not show any differences from 
the data reported in a previous study (11) (Table 4). However, 
the typing of different KIR2DS4 alleles (27) revealed an increased 
frequency of the functional KIR2DS4 alleles (KIR2DS4-FL) in 
patients with CHCV infections (0.52 vs. 0.42 in healthy controls, 
p = 0.02) (Table 5). Similarly, the deleted forms (KIR1D) showed 
a decreased frequency of the homozygous KIR1D genotype 
and a clear tendency toward an increase in the frequency of 
the homozygous KIR 2DS4FL genotype in patients with CHCV 
infections.
Killer cell immunoglobulin-likereceptors must recognize 
their ligands to perform their functions. Among the inhibitory 
KIRs, KIR2DL1 recognizes HLA-C2 allotypes containing a 
lysine at position 80 of the HLA-Cα1 domain and KIR2DL2/3 
recognize HLA-C1 alleles containing Ser77/Asp80 (28, 29). 
However, KIR2DL2 and, to some extent, KIR2DL3 interact with 
some C2 alleles with weaker affinity than KIR2DL1. The geno-
type frequency of individuals with a known ligand is shown in 
Table 6. After analyzing the whole population of CHCV patients, 
the comparison between healthy individuals and CHCV patients 
showed no significant differences.
expression of Kir receptors in chcV 
Patients
In contrast to the genotype frequency, the expression of KIR 
genes in PBMCs from patients with CHCV infections showed 
differences compared with PBMCs from healthy controls. NK 
(CD56+CD3−), NKT (CD3+CD56+), and T (CD3+) cells were 
analyzed. CD56dim cells from CHCV patients carrying the KIR 
gene showed higher expression of KIR2DS1 (10.1 vs. 5.3% in 
CD56dim cells from healthy controls, p  =  0.003) (Figure  1C) 
and KIR3DL2 (22.5 vs. 15.1% in healthy controls, p  =  0.009) 
(Figure 1C) and lower expression of KIR3DL1 (11.4 vs. 16.4% 
in healthy controls, p  =  0.04) (Figure  1C). CD3+CD56+ cells 
also showed increased expression of KIR3DL2 (12.3 vs. 7.1% in 
healthy controls, p = 0.02) and KIR2DS4 (13.3 vs. 4.0% in healthy 
controls, p = 0.01) (Figure 1D). No differences were found in the 
expression of KIRs within CD56bright NK cells (Figure  1B) and 
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patients, and healthy LMCs were collected from untreated indi-
viduals. LMCs from CHCV patients were collected before liver 
transplantation on previously treated patients. However, LMCs 
from CHCV patients showed levels of KIR expression that were 
similar to those in LMCs from healthy controls (Figures 1F–I). 
Expression was measured only in individuals carrying the KIR 
gene, which partially explains the small number of CHCV-
infected liver samples examined.
nK and T cell Populations in Patients with 
chcV infections
Compared with those from healthy controls, PBMCs from 
CHCV patients showed decreased frequencies of CD56dim 
NK cells (6.5 vs. 8.3%, p = 0.002) and CD3+CD56+ cells (2.0 vs. 
3.8%, p =  0.001) (Figure  2A). Similarly, decreased frequencies 
of CD56dim NK cells (5.0 vs. 12.2% in CD56dim cells from healthy 
controls, p < 0.001) and CD56bright cells (5.4 vs. 15.0% in healthy 
controls, p  <  0.001) (Figure  2B) were detected in the liver of 
CHCV patients, but the CD56dim/CD56bright ratio was maintained 
(50% of each subset). Livers of CHCV patients showed significant 
infiltration of T lymphocytes, suggesting that the decrease in the 
frequency of NK cells occurred at the expense of an increase in 
the frequency of T  lymphocytes (79.1 vs. 54.5% in peripheral 
blood, p < 0.001). The lack of changes in the frequency of liver 
CD3+CD56+ cells indicates that the increase in the frequency of 
T cells observed in CHCV patients involved T cell subsets aside 
from CD3+CD56+ cells (Figure 2B).
expression of Other nK cell Markers in 
chcV Patients
Compared with those from healthy controls, PBMCs-CD56bright 
NK cells from CHCV patients showed no differences in the 
expression of CD94, NKG2A, NKG2C or CD16 (Figure 3A). In 
contrast, PBMCs-CD56dim NK cells from CHCV patients showed 
a decreased frequency of CD16 expression (69.5 vs. 92.0%, 
p = 0.002; Figure 3B). Similarly, liver CD56dim cells maintained 
the same low expression of CD16 in liver healthy controls 
(Figure 3D), which implies a potentially lower capacity to exert 
ADCC. We detected more frequent expression of the activating 
receptor NKG2C in the liver CD56bright cells from patients with 
CHCV infections (13.2 vs. 4.2% in healthy controls, p  =  0.04; 
Figure 3C).
nK receptors and the clinical course of 
hcV infection
We next evaluated the correlations of altered expression of NK 
receptors with clinical features of CHCV patients.
Association with BMI
KIR3DL2 expression was decreased in CD56bright NK cells, CD56dim 
NK cells, and CD3+CD56+ cells from CHCV patients with high 
BMI (>25) (3 vs. 11% in those with normal BMI, p = 0.002; 16 vs. 
31% in those with normal BMI, p = 0.009; and 6 vs. 23% in those 
with normal BMI, p < 0.02, respectively; Figure 4A). KIR3DL2 
expression was further increased in CHCV patients with normal 
BMI compared with healthy subjects. Furthermore, an association 
Table 5 | Genotype frequencies of the KIR2DS4-FL+ gene in chronic HCV 











259 0.42 0.18 0.24 0.58
CHCV 316 0.52* 0.25 0.27 0.48*
*p < 0.05; Fisher’s exact test.
Table 4 | Genotype frequencies of killer cell immunoglobulin-like receptor (KIR) genes.
Kir n 2Dl1 2Dl2 2Dl3 2Dl4 2Dl5 3Dl1 3Dl2 3Dl3 2Ds1 2Ds2 2Ds3 2Ds4 2Ds5 3Ds1 2DP1 3DP1
Healthy Ind. 273 0.95 0.61 0.85 1.00 0.55 0.95 1.00 1.00 0.40 0.58 0.29 0.95 0.35 0.40 0.95 1.00
Chronic HCV 351 0.97 0.60 0.88 1.00 0.58 0.93 1.00 1.00 0.45 0.59 0.34 0.90 0.38 0.47 0.97 1.00
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was observed between BMI and KIR3DL2 expression in CD56bright 
NK cells and CD56dim NK cells when the variables were expressed 
as continuous values (r value = 0.63, p = 0.001, and r value = 0.45, 
p = 0.03, respectively; Spearman’s test).
Association with Transaminase (SGPT/SGOT) 
Activity Levels
Consistent with the increased frequency of KIR2DS4-FL gene 
expression in CHCV patients, its expression was detected in 
peripheral blood CD56dim NK  cells with elevated transaminase 
levels (more than twofold higher than the upper limit of normal, 
Figure 4B) (42 vs. 31% in cells with normal transaminase levels, 
p < 0.05). However, the r value calculated using Spearman’s test 
was not significant when the variables were expressed as continu-
ous values, although a trend was observed (r value 0.40, p = 0.17, 
Spearman’s test).
Association with the Time of Infection
Among CHCV patients, we were able to identify the approximate 
time of the infection in a subgroup (most cases were due to intra-
venous drug addiction or transfusion of blood). In our cohort, 
the median time that had elapsed since infection was 27 years. 
According to the time since HCV infection, patients were 
divided into early-infected (less than 27 years) and late-infected 
subgroups (more than 27 years).
As described above, inhibitory KIR3DL1 expression 
was decreased in the whole CHCV-infected patient cohort. 
Furthermore, KIR3DL1 expression was also decreased in periph-
eral blood CD56dim NK cells (together with its Bw4 ligand) from 
the group of early-infected patients who developed cirrhosis 
(5 vs. 32% in patients without cirrhosis, p =  0.03; Figure  4C). 
Within the group of late-infected patients, individuals with 
cirrhosis displayed lower expression of the strong inhibitory 
receptor NKG2A in peripheral blood CD56bright NK cells (79 vs. 
94% in patients without cirrhosis, p = 0.02, Figure 4C). However, 
KIR3DL1 and NKG2A did not show correlations with the time of 
infection when the variables were expressed as continuous vari-
ables (Spearman’s test). Thus, we postulated that lower KIR3DL1 
expression during early infection or NKG2A expression during 
late infection may contribute to progression to cirrhosis.
Association with Necroinflammatory Activity
Chronic HCV patients with high necroinflammatory activity (a 
METAVIR score ≥ 2) are expected to rapidly progress to fibrosis. 
Patients presenting high necroinflammatory activity displayed an 
increase in the expression of the CD94/NKG2C activator heter-
odimer in their peripheral blood CD56dim NK cells (58 vs. 34% in 
those with lower necroinflammatory activity, p = 0.01 for CD94, 
and 24 vs. 3.5%, p = 0.04 for NKG2C; Figure 4D). Moreover, the 
r value calculated using Spearman’s test was not significant when 
the variables were expressed as continuous values.
Association of the Expression of the KIR2DS3 and 
KIR2DS4-FL Genes with the Viral Load and 
Cirrhosis
The viral load was arbitrarily grouped into three levels: 
low < 100,000 IU/ml, intermediate between 100,000–500,000 IU/
ml and high ≥500,000  IU/ml. CHCV patients with a high 
viral load had a higher frequency of the KIR2DS3 genotype 
compared with patients with an intermediate viral load (44 vs. 
20%; p < 0.05, OR: 3.2; Figure 5A). Strikingly, KIR2DS3, which 
is present in 29% of the Argentinian population (30), was not 
detected in any patients with a low viral load. Furthermore, the 
differences in the frequency of the KIR2DS3 genotype in patients 
with low viral loads and patients with intermediate and high viral 
loads were even more significant (44 and 20 vs. 0%, p  =  0.04, 
OR: 9.8). Similarly, an increased frequency of the KIR2DS4-FL 
genotype was observed in patients with intermediate and high 
viral loads compared to patients with low viral loads (56 and 42 
vs. 8%, p < 0.01, OR: 9.8; Figure 5A). Based on these findings, the 
presence of the activating genes 2DS3 and 2DS4-FL was associ-
ated with a high viral load. Furthermore, homozygosity for the 
KIR2DS4-FL genotype was also associated with progression to 
cirrhosis (33 vs. 19% in the non-cirrhotic group, p = 0.03, OR: 
2.1; Figure 5B).
Sex
We did not detect differences according to sex (185 men and 166 
women).
Functional studies of nK and T cells in the 
livers of Patients with chcV infections
We postulated that degranulation, as measured by CD107a stain-
ing, is a representative marker of cytotoxicity. Compared with 
healthy livers, liver CD56bright, and CD56dim cells from CHCV 
patients showed an increased cytotoxic capacity (71.1 vs. 42.5%, 
p < 0.05, and 47.0 vs. 18.8%, p < 0.05, respectively; Figure 6). 
Similarly, liver CD3+CD56+ and T  cells from CHCV patients 
also showed a higher cytotoxic capacity (79.3 vs. 35.0, p = 0.03, 
and 53.5 vs. 26.7%, p = 0.03, respectively). In contrast, patients 
Table 7 | Relationship of natural killer (NK) receptors with the clinical evolution 
of chronic HCV patients.
Factor nK receptor gene/expression
Transaminase activities KIR2DS4 CD56dim
Body mass index KIR3DL2 CD56bright, CD56dim, 
NKT
Evolution to cirrhosis KIR3DL1+ ligand and NKG2A CD56dim, CD56bright
Inflammation CD94/NKG2C CD56dim
Viral load KIR2DS4-FL and KIR2DS3 Gen
Cirrhosis KIR2DS4-FL Gen
Table 6 | Frequencies of killer cell immunoglobulin-like receptor (KIR) genes and their ligands.
2dl1+ hla-c2 2dl2+ hla-c1 2dl3+ hla-c1 3dl1+ hla-bw4 3dl2+ hla-a 
*03/*011
2ds1+ hla-c2 2ds2+ hla-c1 2ds4 fl+ Putative 
ligands
Healthy Ind. 0.64 0.86 0.82 0.66 0.26 0.64 0.84 0.60
Chronic HCV 0.64 0.87 0.85 0.64 0.27 0.68 0.87 0.62
The analyses were performed on CHCV patients and healthy controls possessing the KIR gene. The n value for each KIR gene was deduced from the genotype frequencies shown 
in Tables 4 and 5. Fisher’s exact test.
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and healthy controls displayed a similar capacity to secrete IFNγ 
(Figure 6).
expression of Differentiation/activation 
Markers in nK and T cells from chcV 
Patients
Peripheral blood CD56bright and CD56dim cells from CHCV 
patients showed decreased expression of CD45RA (89.1 vs. 
95.4% in healthy controls, p = 0.02, and 98.0 vs. 100.0 in healthy 
controls, p = 0.01, respectively; Figures 7A,B). This profile was 
even more evident in the liver CD56bright and CD56dim cells (69.6 
vs. 96.2% in healthy livers, p  <  0.0001, and 82.5 vs. 97.0% in 
healthy livers, p = 0.009, respectively; Figures 7E,F). Loss of this 
marker suggests that the cell population included more activated 
NK cells. On the other hand, CD161 expression was markedly 
increased in peripheral blood CD56bright cells from CHCV patients 
(68.0 vs. 40.3% in healthy controls, p = 0.0008). Peripheral blood 
T  lymphocytes from patients with CHCV infections displayed 
decreased expression of the markers CD45RA, CD27, and CD28 
(33.8 vs. 54.2% in healthy controls, p = 0.004, 83.0 vs. 95.2% in 
healthy controls, p = 0.009, and 77.6 vs. 90.1% in healthy controls, 
p = 0.002, respectively; Figure 7D). A similar trend was observed 
for the expression of CD45RA, CD28, and CD27 in CD3+CD56+ 
PBMCs (Figure 7C) and in hepatic T and CD3+CD56+ lympho-
cytes (45.7 vs. 69.0% in healthy livers, p  =  NS, 38.3 vs. 58.3% 
in healthy livers, p = NS, and 26.0 vs. 65.1%, p = 0.03, 23.7 vs. 
41.1%, p < 0.05, respectively; Figures 7G,H). Thus, the increased 
frequency of T cells in the livers of CHCV patients is associated 
with a more differentiated stage.
DiscUssiOn
The role of NK  cells in acute HCV infections has been widely 
evaluated. Most of these studies analyzed either the genomic 
expression of KIR receptors and their ligands or the expression 
of NK  cell markers in peripheral blood (4, 6, 31, 32). In the 
present study, we examined the role of NK and T cells in CHCV 
patients and analyzed the KIR genotype and their protein levels 
on the surface of peripheral blood and liver cells. As previously 
reported (16), healthy livers show an enrichment of CD56bright 
and CD56dim NK cells, which represent approximately half of the 
LMCs. Compared with healthy controls, PBMCs from CHCV 
patients featured decreased frequencies of CD56dim NK  cells. 
Similarly, decreased frequencies of CD56dim and CD56bright 
NK cells were detected in the livers of CHCV patients, but the 
CD56dim/CD56bright ratio was maintained in NK  cells. Because 
the livers of CHCV patients showed significant infiltration of 
T lymphocytes, we postulated that in contrast with PBMCs, the 
decreased frequency of NK cells was related to a higher frequency 
of T cells. In this context, T cells in the peripheral blood and liver 
from CHCV patients showed a more differentiated phenotype, 
with fewer naive cells.
As described in previous studies by our group and others 
(20, 33, 34), key differences are detected between liver-resident 
NK cells and NK cells from blood, regardless of the liver pathol-
ogy. This finding was corroborated in the present study because 
we did not observe phenotypic differences between LMCs 
from patients with CHCV infections and LMCs from healthy 
controls. Notably, PBMCs from patients with CHCV infections, 
and healthy LMCs were obtained from untreated individuals. 
LMCs that were obtained from patients with CHCV infec-
tions before liver transplantation were collected from treated 
individuals.
The cytotoxic capacity of the liver during CHCV infection 
has been controversial. Some reports have described decreased 
cytotoxic capacity (35, 36) as an increase in the number of the 
CD56bright CD45RA-negative NK  cells with high secretory and 
cytotoxic capacity (37). Likewise, compared with the liver cells 
from healthy individuals, we detected increased cytotoxic capac-
ity of liver CD56bright and CD56dim NK cells in association with 
an increase in NKG2C expression and a decrease in CD45RA 
expression in both NK subsets in patients with CHCV infec-
tions. In addition, increased expression of the activating receptor 
NKG2C was observed, which would reduce the activation thresh-
old of these cells in the presence of their ligand HLA-E a molecule 
present in Kupffer cells, hepatocytes, and all mononuclear cells 
(38). The expansion of the CD94/NKG2C activator heterodimer 
detected in this cohort of CHCV patients is also typically detected 
in peripheral blood CD56dim NK  cells in response to human 
cytomegalovirus (CMV) infection (39). However, the number of 
subjects with these expansions did not differ between patients 
with CMV-seropositive viral hepatitis and corresponding 
healthy controls (40). Thus, this NKG2C expansion may reflect 
FigUre 1 | Differences in the expression of killer cell immunoglobulin-like receptor (KIR) genes in the following cell subsets from chronic HCV (CHCV) patients and 
healthy controls: (a) Each KIR on the X axis is represented by its corresponding letter. peripheral blood mononuclear cell (PBMCs): (b) CD56bright, (c) CD56dim, (D) 
NKT (CD3+CD56+), and (e) T cells; liver mononuclear cells (LMCs): (F) CD56bright, (g) CD56dim, (h), NKT (CD3+CD56+), and (i) T cells. Each bar shows the median 
expression of positive cells for each KIR and the IQR. *p < 0.05, **p < 0.01, Mann–Whitney U test.
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FigUre 3 | Expression of natural killer (NK) cell markers in peripheral blood lymphocytes (a,b) and liver mononuclear cells (LMCs) (c,D) from healthy and chronic 
HCV (CHCV)-infected individuals. The black line indicates median expression of the specific marker within the CD56bright and CD56dim populations. **p < 0.01, 
Mann–Whitney U test.
FigUre 2 | (a) Comparison of CD56bright, CD56dim, NKT (CD3+CD56+), and T lymphocyte subpopulations in peripheral blood between healthy individuals and 
chronic HCV (CHCV) patients. (b) Comparison of liver cell subpopulations between healthy individuals and CHCV patients. The results are expressed as 
percentages of positive cells within each subpopulation. Black lines indicate median expression. **p < 0.01, ***p < 0.001, Mann–Whitney U test.
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an underlying CMV infection, because approximately 80% of the 
Argentinian population is seropositive for CMV.
We detected increased expression of CD107a, a marker of 
degranulation that is usually used as a marker of cytotoxicity in 
CD56bright NK cells, CD56dim NK cells, CD3+CD56+, and T cells 
from patients with CHCV infections. However, we should be cau-
tious in interpreting these findings because recent studies (41, 42) 
have reported that liver-resident NK and T cells have the ability 
to degranulate but lack expression of cytotoxic mediators. Thus, 
the use of different methods to explore the ability of liver NK cells 
to kill target cells may explain the discrepancy in the results. In 
addition, the expression of FcγRIII, the CD16 activating recep-
tor that is an essential mediator of ADCC, is downregulated on 
liver NK cells, which could explain the decrease in liver ADCC. 
CHCV infection induces NK cell activation, resulting in ADAM-
17-dependent CD16 shedding and subsequent impairments 
FigUre 4 | (a) Expression of KIR3DL2 in CD56bright, CD56dim, and NKT (CD3+CD56+) cell populations in peripheral blood from patients with normal body mass index 
(BMI) (≤25, n = 11) or elevated BMI (>25, n = 12). (b) Expression of KIR2DS4 in peripheral blood CD56dim cells from patients with normal (<2) or elevated (≥2) liver 
transaminase levels. (c) Decreased expression of KIR3DL1 + Bw4 in CD56dim cells from early cirrhotic patients (left) and decreased expression of NKG2A in 
CD56bright cells from late-infected patients. (D) Increased expression of CD94 and NKG2C in peripheral blood CD56dim cells from chronic HCV patients with high 
levels of necroinflammatory activity (≥2) compared with patients with low necroinflammatory activity (<2). Black lines indicate the medians of positive cells. *p < 0.05, 
**p < 0.01, Mann–Whitney U test.
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in ADCC (43). Altered ADCC may contribute to the failure to 
eradicate the HCV infection. In contrast, patients and healthy 
controls displayed a similar capacity to secrete IFNγ.
The typing of the KIR and HLA genes showed no differences 
between CHCV patients and controls, and this finding nearly 
coincided with a previous report from our laboratory (11). 
However, we detected an increased frequency of the functional 
alleles of KIR2DS4-FL. We next explored putative associations 
of the expression of KIR genes and lectin-type C receptors with 
clinical factors that predict progression to fibrosis and cirrhosis. 
Interestingly, homozygosity for KIR2DS4-FL, the frequency 
of which was increased in patients with CHCV infections, was 
associated with the presence of cirrhosis. This gene dosage effect 
may have a significant biological impact on patients with CHCV 
infections (44, 45), because individuals with two copies of the 
respective gene would exhibit increased expression. Furthermore, 
the expression of the KIR2DS4-FL gene was increased in CHCV 
patients with intermediate and high viral loads. In addition, an 
increased frequency of KIR2DS4 expression was detected in 
CD56dim NK cells from CHCV patients with elevated transami-
nase activity levels. Based on these results, we speculate that the 
increased frequency of the KIR2DS4 genotype may be a conse-
quence of reduced capacity to spontaneously resolve the HCV 
infection in the acute phase, causing its enrichment in CHCV 
patients alternatively, KIR2DS4 may be involved in the chronic 
evolution of the infection by inducing damage to the hepatic 
parenchyma.
In a previous genetic analysis (11), KIR2DS3 expression was 
increased in CHCV patients with elevated transaminase levels. 
We have now determined that KIR2DS3 expression was also cor-
related with high or intermediate viral loads in patients. Notably, 
KIR2DS3 was not expressed in any patients with a low viral load. 
In contrast to our data, KIR2DS3 expression was associated with 
a low viral load in the absence of KIR2DS5 expression in another 
study (12). Importantly, KIR2DS3 was present in only 29% of our 
population (30) but is expressed in 37% of CHCV who progress 
toward cirrhosis (11). Consistent with our results, KIR2DS3 has 
been reported to be a risk factor for the development of CHCV 
infection (46) and has also been associated with the failure to 
respond to HCV treatment (47). In addition to the lack of an 
identified ligand, KIR2DS3 is not detected at the NK cell surface, 
and a KIR gene in linkage disequilibrium with KIR2DS3 may 
be associated with its clinical effects (48, 49). We also detected 
decreased expression of KIR3DL1 and increased expression of 
KIR3DL2 in CD56dim NK cells within the whole cohort of CHCV 
patients. Of clinical relevance, decreased expression of KIR3DL1 
FigUre 6 | (a) Comparison of the cytotoxic capacity (indirectly measured as CD107a expression) and (b) secretory capacity (evaluated by measuring IFNγ 
production) of liver lymphocytes between healthy individuals (n = 4) and chronic HCV (CHCV) patients (n = 4). Black lines indicate the medians of cells positive for 
the different populations CD56bright, CD56dim, NKT (CD3+CD56+), and T cells. *p < 0.05, Mann–Whitney U test.
FigUre 5 | (a) Frequency of the KIR2DS3 and killer cell immunoglobulin-like receptor (KIR) 2DS4-FL genotypes in patients with low (<100,000 IU/ml, n = 12), 
intermediate (100,000–500,000 IU/ml, n = 25), and high (≥500,000 IU/ml) viral loads (n = 59). (b) Frequency of the homozygous KIR2DS4-FL genotype in cirrhotic 
(n = 88) and non-cirrhotic patients (n = 119). The frequencies were multiplied to be expressed as a percentage. *p < 0.05, **p < 0.01, ***p < 0.001; Chi-square test 
analyzed using the maximum likelihood method for low viral load vs. intermediate and high viral loads and for intermediate viral load vs. high viral load (Pgc < 0.05). 
For the analysis in (a), the p-value was corrected using Bonferroni’s method. Fisher’s exact test was used for the analysis shown in (b).
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FigUre 7 | Differences in the expression of differentiation/activation markers in the following cell subpopulations from chronic HCV (CHCV) patients and healthy 
controls: Peripheral blood mononuclear cell (PBMCs): CD56bright (a), CD56dim (b), NKT (CD3+CD56+) (c), and T cells (D); liver mononuclear cells (LMCs): CD56bright 
(e), CD56dim (F), NKT (CD3+CD56+) (g), and T cells (h). The results are expressed as percentages of positive cells for each killer cell immunoglobulin-like receptor 
(KIR). *p < 0.05, **p < 0.01, Mann–Whitney U test.
in the presence of its ligand was observed in peripheral blood 
CD56dim NK cells from patients who did not progress to cirrhosis 
in the group of early-infected CHCV patients, suggesting that 
lower expression of KIR3DL1 may delay progression to cirrhosis. 
Similarly, in the group of late-infected CHCV patients, we observed 
an association between cirrhosis and lower expression of the 
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strong inhibitory receptor NKG2A in peripheral blood CD56bright 
NK cells. Consistent with our results, a decreased frequency of 
KIR3DL1 expression along with a concomitant increase in the 
surface expression of NKG2D on NK cells was also reported in 
CHCV patients (36). We also detected that an activated state was 
related to high necroinflammatory activity and more rapid pro-
gression toward fibrosis. These findings suggest that an increased 
frequency of an activator receptor or a decreased frequency of its 
inhibitory counterpart is associated with the clinical evolution 
of the HCV infection (Table 7). According to a recent report 
(50), genetic factors largely determine the expression of inhibi-
tory receptors, whereas activating receptors are substantially 
influenced by the environment. CHCV infection is known to 
induce NK cell activation (43). Therefore, the activation state of 
liver NK cells explains the restricted expression of KIR-activating 
genes in liver T cells, as well as the association of KIR-activating 
genes with CHCV infection.
The expression of KIR3DL2 was decreased in CD56dim and 
CD56bright NK cells. These alterations were associated with a high 
BMI and may be factors associated with the greater progression 
to fibrosis among CHCV patients.
Our results indicate that an increased frequency of activating 
receptor expression or a decreased frequency of expression of its 
inhibitory counterpart may be associated with a worse clinical 
evolution during the chronic phase of the HCV infection, in 
contrast to the acute phase of an HCV infection. These changes 
should be evaluated in the context of a more differentiated/acti-
vated state of peripheral blood and liver T cells and NK cells, and 
their increased capacity to degranulate may reflect an increase in 
their cytotoxic activity. A proposed hypothesis is that in patients 
with CHCV infections, individuals who are more likely to have 
activated NK and/or CD3+ CD56+ cells would exhibit evolution 
of the disease. Further studies are required to confirm our results 
concerning the role of the expression of KIR genes in the progres-
sion of HCV infection.
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FigUre s1 | Illustrative scheme for the analysis of killer cell immunoglobulin-
like receptor (KIR) expression in peripheral blood mononuclear cells (a) and 
liver mononuclear cells (LMCs) (b) on CD56dim natural killer cells in a healthy 
individual. The expression of 2DS3 was deduced after subtracting the 
expression detected by anti-2DL1/2DS1/2DS3 (1) the frequency detected by 
2DL1/2DS1 (2) 0.2DS1 was deduced by subtracting the expression of 2DL1 (3) 
from the expression detected using the 2DL1/2DS1 antibody (2). The 
expression of 2DL2/2DS2 was inferred after subtracting the expression 
detected by the anti-2DL3 antibody (5) to the expression detected by the 
anti-2DL2/2DS2/2DL3 antibody (4). In all cases, the presence of the KIR gene 
was verified.
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